MicroRNA let-7a Modifies the Effect of Self-Renewal Gene HIWI on Patient Survival of Epithelial Ovarian Cancer. by Lu, L et al.
 1 
MicroRNA let-7a Modifies the Effect of Self-renewal Gene HIWI on Patient 1 
Survival of Epithelial Ovarian Cancer  2 
 3 
 4 
Lingeng Lu1,*, Dionyssios Katsaros2, Harvey A Risch1, Emilie Marion Canuto2, 5 
Nicoletta Biglia4,  Herbert Yu1, 3 6 
 7 
 8 
 9 
 10 
1. Department of Chronic Disease Epidemiology, School of Public Health, School of 11 
Medicine, Yale Cancer Center, Yale University, New Haven, CT 06520-8034, USA 12 
2. Department of Surgical Science , A O Città della Salute e della Scienza di Torino,  13 
S.Anna Hospital, 10126 Turin, Italy 14 
3. Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI 15 
96813, USA 16 
4. Department of Surgical Science, Division of Obstetrics and Gynecology, University 17 
of Torino, Mauriziano Hospital, 10128 Turin, Italy 18 
 19 
*Corresponding Author: 20 
Dr. Lingeng Lu, Department of Chronic Disease Epidemiology, School of Public 21 
Health, School of Medicine, Yale University, 60 College Street, New Haven, CT 22 
06520-8034, USA. Phone: 203-737-6812, Fax: 203-785-2207, Email: 23 
lingeng.lu@yale.edu 24 
 25 
 26 
 27 
Running title: HIWI and let-7a interplay in ovarian cancer prognosis 28 
 29 
 30 
 31 
 32 
 33 
Key Words:  Epithelial ovarian cancer, piwi-like RNA-mediated gene silencing 1 34 
(PIWIL1, or  HIWI), let-7a, prognosis, chemotherapy 35 
Abstract: 248 words, Text: 3451 words.  36 
 37 
1 figure, 5 tables 38 
 39 
 40 
 41 
 42 
 2 
Abstract 1 
Aberrant expressions of self-renewal gene HIWI and microRNA let-7a are in epithelial 2 
ovarian cancer (EOC). A U-shape association between HIWI expression and overall 3 
survival is seen in several human cancers but unknown in EOC. HIWI physically binds 4 
let-7a, but the clinical relevance of this interaction is yet to be addressed.  Here we 5 
analyzed HIWI and let-7a expressions in 211 primary EOC tissues using quantitative 6 
reverse transcription PCR to investigate HIWI and its interaction with let-7a in the 7 
prognostic significance of EOC. Associations of HIWI and its interaction with miRNA 8 
let-7a with patient survival were analyzed using the Kaplan-Meier survival curves and 9 
Cox proportional hazard regression models.  Kaplan-Meier survival curves showed that 10 
patients with medium HIWI had poorer overall survival than those with low or high 11 
HIWI. An 89% increased death risk (HR = 1.89, 95% CI: 1.29 – 2.98) was observed in 12 
the medium HIWI group in multivariate Cox proportional hazard regression analyses. 13 
Among patients with high let-7a expression, those with medium HIWI had an increased 14 
risk of death compared to those with low HIWI (HR = 2.62, 95% CI: 1.30 – 5.30), 15 
whereas among those with low let-7a, no significant association between HIWI 16 
expression and overall survival was observed (HR = 1.63, 95% CI: 0.86 – 3.08). 17 
Moreover, HIWI expression also affected chemotherapy response. The results suggested 18 
that miRNA let-7a could modify the effect of HIWI expression on patient survival of 19 
EOC, expanding our understanding of the clinical relevance of HIWI and let-7a 20 
interaction in EOC prognosis.  21 
  22 
 23 
 3 
Introduction 1 
HIWI (also known as piwi-like RNA-mediated gene silencing 1, PIWIL1), located on 2 
chromosome 12q14.33, is a member of the P-element induced wimpy testis (PIWI) gene 3 
family in humans [1]. This family is evolutionarily conserved across species; their 4 
encoded-proteins are highly homologous, particularly in the carboxy-terminus [1]. The 5 
HIWI is a ribonucleoprotein in the length of 861 amino acids, which contains a N-6 
terminal PIWI/Argonaute/Zwille (PAZ) domain and a PIWI domain at the carboxy-7 
terminus [2-4]. The PAZ domain binds to single-stranded small RNA, and the PIWI 8 
domain functions as an RNase H endonuclease cleaving target RNA complementarily 9 
bound to small RNA [4-6]. The involvement of HIWI proteins in the regulation of gene 10 
expression is through their interacting partners of small non-coding RNAs such as 11 
namely PIWI-associated RNAs (piRNAs) [7]. Nuclear HIWI controls retrotransposon 12 
silencing via affecting DNA methylation [8-10]. Recently, Sequencing results of 13 
Immunoprecipitation (IP) against HIWI show that HIWI interacts with miRNAs 14 
including let-7a in fining gene expression [11]. Moreover, it has also been reported that  15 
HIWI can be a partner interacting with Dicer, a key RNase III endonuclease in miRNA 16 
maturation [12-14]. These findings suggest HIWI is also localized in cytoplasm and 17 
may participate in the role of miRNAs in gene regulation. The HIWI gene is expressed 18 
in hematopoietic stem cells and germ cells but not in differentiated cells. It has been 19 
evidenced that HIWI plays an important role in maintaining stem cell renewal 20 
[1,7,15,16]. In the PIWI mutant models, germline stem cell asymmetric divisions cannot 21 
be functionally processed in both male and female flies, leading to a loss of germline 22 
stem cells and a reduced number of eggs and sperms during oogenesis or 23 
 4 
spermatogenesis [7,17]. In healthy women, those with age younger than 50 years old 1 
express HIWI in ovary tissues [18].   2 
Aberrant HIWI expression is associated with tumorigenesis and with cancer patient 3 
survival. Over-expressed HIWI has been observed in seminomas testicular tumors but 4 
not in nonsemnomatous, spermatocytic seminomas and somatic types [1,19]. A large 5 
number of gastric cancers show increased HIWI expression in comparison to normal 6 
tissues, and HIWI has been involved in the proliferation of gastric cancer cells [20]. 7 
Both U-shape and linear associations between HIWI expression levels and cancer 8 
patient survival have been observed. Compared to moderate expression, both low and 9 
high HIWI expression were reported to be associated with increased death in patients 10 
with soft-tissue sarcoma, suggesting that HIWI may have biphasic effects on tumor 11 
progression [21,22]. Recently, Grochola et al. reported that HIWI expression increased 12 
pancreatic cancer-related death but in a male-specific manner [23]. Prognostic value of 13 
HIWI has been shown in several human solid tumors including hepatocellular 14 
carcinoma [24], colorectal cancer [25], glioma [26], and esophageal carcinoma [27]. 15 
Very recently, it has also been shown that the expression of HIWI was significantly 16 
higher in epithelial ovarian cancer than in normal ovaries and benign tumors, while 17 
enforced overexpression of HIWI in SKOV3 ovarian cancer cell line led to reduced 18 
metastatic capacity [18], suggesting moderate HIWI expression may associate with 19 
tumor development and progression in ovarian cancer.  However, whether HIWI 20 
expression has prognostic value in ovarian cancer is yet to be investigated. 21 
 22 
 5 
MicroRNA let-7a is one member of let-7 family, which is one well-characterized 1 
miRNA in controlling gene expression, and plays important roles in cell proliferation, 2 
differentiation, apoptosis and metabolism [28-30]. Dysregulated let-7a has been 3 
reported in different types of human cancer [31-34], and associates with cell 4 
proliferation, chemotherapy response, and patient survival [35-37]. Moreover, the 5 
involvement of let-7a has been demonstrated in stemness [38-40]. Our previous study 6 
also showed that let-7a was associated with epithelial ovarian cancer survival [37]. 7 
Given that cytoplasmic HIWI protein can interact with let-7a directly [11] or indirectly 8 
through miRNA maturation-associated protein Dicer, which could form a negative 9 
feedback loop with let-7a [41], and that both HIWI and let-7a are involved in the 10 
maintenance of stem cells [1,7,15,16,42], we speculate that HIWI and let-7a may 11 
orchestrate in executing biological functions. Thus, the purposes of this study were to 12 
determine HIWI expression and its interaction with let-7a in the prognosis of epithelial 13 
ovarian cancer.     14 
 15 
Materials and Methods 16 
Patients and tumor samples  17 
In this study, a written informed consent was obtained from each individual of the 18 
participants, and all subjects in this study were de-identified for the sake of participants’ 19 
privacy. With the approval of the University’s ethical review committee, 211 women 20 
diagnosed with epithelial ovarian cancer were enrolled between October 1991 and 21 
February 2000 in the Department of Gynecology and Obstetrics at University of Turin 22 
in Italy.  Fresh tumor tissues were collected for the study at surgery. Disease stage and 23 
 6 
tumor grade were determined for each patient according to the International Federation 1 
of Gynecology and Obstetrics Classification (FIGO) and WHO criteria [43,44]. Most of 2 
the patients received standard post-operative chemotherapy after cytoreduction surgery 3 
and were subsequently followed up for disease progression until June 2001.  Median 4 
follow-up time was 31 months, ranging from 0.6 to 114 months.  5 
 6 
There were four categories of treatment response defined in the study. The definition is 7 
as follows: (a) complete response: resolution of all evidence of disease for at least a 8 
month, (b) partial response: a decrease of ≥50% in the product of the diameters 9 
(maximum and minimum) of all measurable lesions without the development of new 10 
lesions for at least a month, (c) stable disease: a decrease of <50% or an increase of 11 
<25% in the product of the diameters of all measurable lesion, and (d) progressive 12 
disease: an increase of ≥25% in the product of the diameters of all measurable lesions or 13 
the development of new lesions. Of the 176 patients with available information on 14 
chemotherapy treatment response, 128 (72.7%) who had complete response was 15 
considered ‘Yes’ response in data analysis, while 48 (27.3%) who were in the other 16 
three categories were grouped as ‘No’ response, which included 36 with partial 17 
response, 4 with stable disease, and 8 with progressive disease.   18 
 19 
Analysis of HIWI and let-7a expression  20 
All tumor samples were examined by two independent pathologists, and the specimens 21 
which contained 80-90% tumor cells were used in this study. Total RNAs extracted 22 
from the tumor samples were used as templates to make cDNA using the Cloned AMV 23 
 7 
First-Strand cDNA Synthesis kit (InvitrogenTM, Carlsbad, CA). The primers for HIWI 1 
and small nucleolar RNA RNU48 (used for normalization) were designed based on 2 
sequences in Genbank (accession number AB274731 for HIWI and X96648 for 3 
RNU48). The primer sequences for HIWI and RNU48 are: HIWI-forward, 5'- CCT GGC 4 
TTC ACT ACT TCC ATC C; HIWI-reverse, 5'- ACG TCA GTG CAG AGC ATG 5 
ATG; RNU48-forward, 5’AGTGATGATGACCCCAGGTAACTC, and RNU48-6 
reverse, 5'- CTG CGG TGA TGG CAT CAG. Real-time PCR was performed to analyze 7 
HIWI expression using the Chromo4TM Real-time PCR System (MJ Research Inc., 8 
Waltham, MA). In the PCR reaction (20 µl), 2 µl of cDNA template was mixed with 10 9 
µl of 2× Power SYBR® Green PCR master mix (Applied Biosystems, Foster City, CA) 10 
and each pair of primers, at final concentrations of 100 nM for both HIWI and RNU48. 11 
PCR amplification included initial incubation at 50°C for 2 minutes, denaturing at 95°C 12 
for 10 minutes, and 40 cycles of denaturing at 95°C for 15 seconds and annealing at 13 
60°C for one minute.  Melting curves were analyzed after each run to verify the size of 14 
PCR product.  15 
Analysis of let-7a expression in tumor tissue was performed using Taqman® microRNA 16 
assay (Applied Biosystems), in which the preparation of miRNA cDNA was made first 17 
using a stem-loop method,  following the manufacturer’s instruction as described in our 18 
previous report [45] . Briefly, levels of let-7a and RNU48 (an internal control for 19 
normalization) expression in the samples were determined with the Taqman® miRNA 20 
assay (Applied Biosystems) using the Chromo4 Real-time PCR System.  In the PCR 21 
reaction (15 µl), 0.3 µl of cDNA template was mixed with 7.5 µl of 2×Taqman® 22 
Universal PCR master mix (Applied Biosystems), 0.75 µl of 20× probe/primers 23 
 8 
(Applied Biosystems) of either let-7a or RNU48, and water.  The PCR amplification 1 
conditions were the same as for the quantification of HIWI gene in this study.  2 
Each sample was analyzed in duplicate, and the analysis was repeated for those with 3 
CV above 5%. 4 
 5 
Statistical analysis 6 
HIWI and let-7a expression was quantified as an expression index (EI), which was 7 
calculated based on the formula 1000 × 2 (−ΔCt), where ΔCt = Cttarget gene – CtRNU48. To 8 
analyze HIWI’s associations with disease features and patient survival, the EI values 9 
were grouped into 3 categories, low, medium and high, which were classified as 10 
undetectable expression, detectable expression below median and detectable expression 11 
equal to or above median, respectively. Let-7a was classified into two groups, low and 12 
high, based on the median of let-7a expression distribution as the cutoff when the 13 
interaction analysis was performed. Associations between HIWI expression and 14 
clinicopathologic factors were analyzed by Chi-square statistic or Fisher’s exact statistic 15 
as appropriate. Survival analysis was performed to assess associations of HIWI 16 
expression with risks of disease progression and death. Cox proportional hazards 17 
regression and Kaplan-Meier survival curves were employed for the survival analyses. 18 
Proportional hazards assumption was also tested in Cox proportional hazards 19 
regression.  All statistical analyses were performed using SAS version 9.2 (SAS 20 
Institute, Cary, NC). All p-values are two-sided. Significant values are shown in bold.  21 
 22 
 23 
 9 
 Results 1 
 2 
Clinical and pathological characteristics of patients  3 
Clinical and pathological features of the 211 participants enrolled in this study were 4 
shown in Table 1.  These patients underwent surgery at ages between 26 to 82 years, 5 
and the median age was 58 years.  Based on the International Federation of Gynecology 6 
and Obstetrics Classification [43], 52 patients were diagnosed with stage I disease 7 
(24.6%), 12 stage II (5.7%), 133 stage III (63.0%), and 14 stage IV (6.6%).  Tumor 8 
grade and histology were determined according to the WHO guidelines [44]. Thirty-9 
four (16.1%) were grade 1 tumors, 40 (19.0%) grade 2 and 137(64.9%) grade 3.  10 
Eighty-five (40.3%) patients had serous tumors, and 126 patients had non-serous tumors 11 
which included 16 (7.6%) clear cell, 41 (19.4%) endometrial, 18 (8.5%) mucinous, 14 12 
(6.6%) müllerian, 1 other (0.5%) and 36 (17.1%) undifferentiated histology.  Surgical 13 
debulking was performed on all the patients. Optimal debulking results were achieved 14 
in 108 (51.9%) patients, and 100 (48.1%) had suboptimal outcomes. Ninety-one 15 
patients (44.0%) had no residual tumor, and 116 (56.0%) had a residual tumor size 16 
greater than 0.  17 
 18 
 19 
Association of HIWI expression with epithelial ovarian cancer prognosis 20 
Of 211 samples, 82 (38.9%), over a third, had undetectable expression of HIWI, and 21 
129 had detectable expression with an average EI of 0.32, ranging from 0.02 to 4.86 22 
(5th-95th percentiles). To investigate the impact of HIWI expression on prognosis of 23 
ovarian cancer, we classified patients based on their HIWI expression into three groups, 24 
low, medium and high, using the EI = 0 (undetectable), >0 to <0.32, and ≥0.32 as 25 
 10 
cutoffs. The numbers of patients in these groups were 82, 65 and 64, respectively. 1 
Kaplan-Meier survival curves showed that patients with low and high HIWI did not 2 
have substantial differences in progression-free or overall survival, but did have more 3 
favorable prognosis than those with medium HIWI expression (data not shown). Based 4 
on this finding and U-shaped associations with death observed elsewhere [21-23], we 5 
combined the low and high groups together, and compared their survival outcomes with 6 
those with medium HIWI expression. Kaplan-Meier survival curves showed that 7 
patients with medium expression had worse overall survival (p = 0.025) (Figure 1). 8 
However, disease progression-free survival was not different by HIWI expression (p = 9 
0.200) (data not shown).  10 
 11 
To confirm the results of Kaplan-Meier analysis and to adjust for potential confounding 12 
factors, we further analyzed the data with the Cox proportional hazards regression. 13 
Proportional hazards assumption test for HIWI expression did not show significance (p 14 
= 0.59). The results of univariate and multivariate analyses were shown in Table 2. Here 15 
too, medium HIWI expression was significantly associated with elevated risk for death 16 
in both univariate and multivariate analyses. After adjustment for patient age at surgery, 17 
disease stage, tumor grade, residual tumor size, histological type and chemotherapy 18 
status, the association remained significant.  The adjusted hazard ratio (HR) was 1.89 19 
(95% CI: 1.29 – 2.98) for high or low HIWI expression compared to medium 20 
expression. In addition, disease stage and residual tumor size showed positive 21 
associations with the risk of death, while chemotherapy treatment improved patient 22 
survival. Their adjusted HRs were 1.71 (95% CI: 1.08 – 2.71) for disease stage, 5.29 23 
 11 
(95% CI: 2.50 – 11.20) for residual tumor size and 0.40 (95% CI: 0.17 – 0.95) for 1 
chemotherapy treatment, respectively. However, the associations of tumor grade, 2 
histological type and patient age at surgery with the risk of death were not statistically 3 
significant. Similarly to the Kaplan-Meier analysis, little evidence of association was 4 
found between disease progression and HIWI expression. Residual tumor size was 5 
positively associated with the risk of relapse. The adjusted HR was 3.00 (95% CI: 1.62 6 
– 5.57).   7 
 8 
Associations of HIWI expression with clinical and pathological features in epithelial 9 
ovarian cancer 10 
We also analyzed associations of HIWI expression with clinical and pathologic 11 
characteristics. A significant association was observed between HIWI expression and 12 
patient response to chemotherapy (p = 0.002). Patients with medium expression of 13 
HIWI had worse response to chemotherapy than those with either low or high 14 
expression. The odds ratio (OR) was 3.01 (95% CI: 1.50 – 6.04) (Table 3). However, no 15 
associations were found between HIWI expression and other clinical and pathologic 16 
variables including disease stage, tumor grade, histological type, residual tumor size and 17 
debulking results.  18 
 19 
Interplay between HIWI and let-7a in epithelial ovarian cancer prognosis 20 
The average EI of let-7a in this study was 4.62 with the range from 0.53 to 35.3 (5th – 21 
95th percentiles).  22 
 12 
Previous studies including immunoprecipitation sequencing results suggest that HIWI 1 
might interplay with let-7a in regulating biological processes [11,15,41,42]. To examine 2 
whether there is any interaction between HIWI and let-7a expressions in the patient 3 
survival of epithelial ovarian cancer, we used the median of let-7a expression as the 4 
cutoff value to classify let-7a into two groups, high (EI  ≥ 4.62, median) and low (EI < 5 
4.62). Then we classified patients into four groups; group 1 with low (EI = 0) or high 6 
(EI ≥0.32) HIWI and low (EI < 4.62) let-7a, group 2 with low or high HIWI and high 7 
let-7a (EI ≥ 4.62, median), group 3 with medium (0 < EI <0.32) HIWI and low let-7a, 8 
and group 4 with medium HIWI and high let-7a. Multivariate Cox proportional hazard 9 
models showed that the adjusted HRs of death were 1.11 (95% CI: 0.66 – 1.86) for 10 
Group 2, 1.64 (95% CI: 0.88 – 3.04) for Group 3, and 2.71 (95% CI: 1.38 – 5.32) for 11 
Group 4 (Table 4) after the adjustment for patient age at surgery, disease stage, tumor 12 
grade, residual tumor size, histological types and chemotherapy status.   However, no 13 
significant associations were found in progression-free survival in the multivariate 14 
analysis.  15 
 16 
We next sought to how HIWI and let-7a modulate each other the effect on patient 17 
survival using stratification analyses (Table 5). When we stratified patients by HIWI 18 
expression levels, we did not find the associations of let-7a expression with overall 19 
survival (p > 0.05) within the strata of either low/high or medium HIWI. In contrast, 20 
when we stratified patients by let-7a expression levels (low and high), we found among 21 
patients with high let-7a expression, medium expression of HIWI significantly 22 
increased the risk of death compared to low/high HIWI expression; the adjusted HR was 23 
 13 
2.62 (95% CI: 1.30 – 5.30). Among those with low let-7a expression, however, no 1 
significant association was found between the risk of death and HIWI expression levels; 2 
the adjusted HR was 1.63 (95% CI: 0.86 – 3.08).   3 
Discussion 4 
This study examined the prognostic value of self-renewal-associated gene HIWI 5 
expression. HIWI expression was detectable in 61% (129 out of 211) epithelial ovarian 6 
cancers, similar to the findings of two previous studies where 7 of 10 gastric cancer 7 
patients and 40 of 56 pancreatic cancer patients showed detectable expression of HIWI 8 
using RT-PCR, and 38 of 50 gastric cancers had positive immunohistochemical stains 9 
for HIWI protein [20,23]. Moreover, Lim and colleagues reported that significantly 10 
upregulated expression of HIWI gene was observed in epithelial ovarian cancer 11 
compared to benign tumors [18]. The lack of association between HIWI expression and 12 
clinical and pathologic variables in our study were in agreement with the investigations 13 
of HIWI in gastric cancer [20] and cervical cancer [46].  14 
  15 
We also investigated the association of HIWI expression in epithelial ovarian cancer 16 
survival. We found that ovarian cancer patients with medium expression of HIWI had 17 
shorter overall survival in comparison to those with low or high expression. This 18 
association was independent of clinical or pathologic factors of the disease. We also 19 
found that patients with medium levels of HIWI expression had poor response to 20 
chemotherapy compared to those with low or high expression. To our knowledge, this is 21 
the first study to examine self-renewal-associated gene HIWI expression and survival of 22 
patients with epithelial ovarian cancer in a clinical setting. Our study showed that 23 
 14 
patients with low or high HIWI expression had a more favorable prognosis. This finding 1 
was similar to, but in the opposite direction of, observations of several previous clinical 2 
studies, which showed that compared to medium, high or low HIWI expression was 3 
associated with elevated death risks in patients with soft-tissue sarcoma and male 4 
patients with pancreatic cancer [21-23]. Our result, however, seems to be more 5 
consistent with findings of a very recent report, in which it was shown that significantly 6 
increased HIWI expression was observed in epithelial ovarian cancer compared to 7 
normal ovarian tissues and benign tumor tissues, while enforced overexpression of 8 
HIWI repressed the invasiveness of ovarian cancer cell SKOV3 [18]. Our findings are 9 
also supported by in vitro experiments that show similar impacts of loss- and gain-of-10 
function of HIWI on cancer cells. Inhibition of HIWI expression in gastric cancer cells 11 
led to G2/M phase arrest and decreased proliferation index of the cancer cells [20], 12 
while high HIWI expression appears to induce apoptosis in tumor cell lines of KG1 13 
[15]. G2/M arrest is a critical step in the initiation of apoptosis [47-49]. Thus, both low 14 
and high HIWI expression may have similar effects on cancer cells. 15 
   16 
Interestingly, previous studies on hepatocellular carcinoma [24] , colorectal cancer [25] 17 
and esophageal squamous carcinoma [27] have shown direct associations between high 18 
HIWI proteins (immunohistochemical staining, IHC) and poor patient survival, but such 19 
correlations have been limited to certain subgroups of patients.  Zhao and colleagues 20 
[24] reported that high HIWI protein was significantly associated with poor prognosis 21 
of hepatocellular carcinoma only in patients with alpha-fetoprotein (AFP) less than 300 22 
ng/ml, but not in those with AFP greater than that level. Zeng and colleagues [25] 23 
 15 
demonstrated that HIWI protein in tissues adjacent to tumor but not in primary tumor 1 
was significantly associated with poor prognosis of colorectal carcinoma. Another study 2 
[27] found that patients with high cytoplasmic but not nuclear HIWI protein had poor 3 
prognosis in esophageal squamous carcinoma, while no association with prognosis was 4 
seen if both cytoplasmic and nuclear HIWI proteins were combined for consideration. 5 
Three possibilities may explain the discrepancy between our and previous studies on the 6 
association of HIWI expression with patient survival. First, translated HIWI from the 7 
mRNAs may be aberrant due to premature stop codon-causing truncation or alternative 8 
splicing, thereby influencing antigen determinants and IHC results, as well as its 9 
function [18]. This aberrant expression of HIWI may result in the phenomenon that it is 10 
high at mRNA levels but low at protein levels. Second, different laboratory methods 11 
were applied to measure HIWI expression (qPCR for mRNA vs IHC for protein); HIWI 12 
expression at mRNA levels measured by qPCR showed biphasic effects, while HIWI 13 
expression at protein levels by IHC had monotonic effects [24,25,27]. Finally, the 14 
association between HIWI expression and cancer prognosis may be tumor or tissue 15 
specific.  16 
 17 
In this study, we also found a significant interaction between HIWI expression and let-18 
7a, increasing the risk of death in epithelial ovarian cancer. Stratification analyses 19 
demonstrated let-7a modified the effect of HIWI expression on overall survival of EOC. 20 
Only at high let-7a levels did patients with medium HIWI expression increase the risk of 21 
death.  This finding supports and extends the previous observation reported by Chen 22 
and colleagues [11], suggesting that HIWI protein not only physically binds let-7a, but 23 
 16 
also orchestrate each other, executing their biological functions.  This also may help to 1 
explain the finding that cytoplasmic but not nuclear HIWI positively associated with 2 
poor prognosis of esophageal squamous carcinoma [27].  3 
As expected, we found disease stage and residual tumor size, two well-established 4 
prognostic risk factors, were unfavorable prognostic indicators, while chemotherapy 5 
treatment improved survival. These results suggest that the findings in this study were 6 
not observed by chance. 7 
 8 
In summary, our study showed that self-renewal gene HIWI was associated with overall 9 
survival as well as chemotherapy response in a U-shape correlation in epithelial ovarian 10 
cancer. Taken together with the recent findings reported by Lim and colleagues [18], 11 
HIWI expression at a moderate level may associate with the increased risk of death and 12 
poor chemotherapy response in epithelial ovarian cancer. We also found the synergetic 13 
effect of self-renewal gene HIWI and miRNA let-7a on patient survival of epithelial 14 
ovarian cancer. These findings suggest that the interplay between self-renewal gene 15 
HIWI and miRNA let-7a has significant clinical relevance in epithelial ovarian cancer 16 
prognosis, and reveal a potential strategy by the modulation of HIWI and let-7a in the 17 
management of epithelial ovarian cancer.   18 
 19 
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Figure legends 11 
 12 
Figure 1. Kaplan-Meier overall survival curves by levels of HIWI expression in 13 
epithelial ovarian cancer. Patients with either low (EI = 0) or high (EI ≥ 0.32) HIWI 14 
expression had better overall survivals than those with medium (0 <  EI < 0.32) 15 
expression (p = 0.025, log-rank test) 16 
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   Table 1 Clinicopathological variables and expressions of HIWI and let-7a in 211 4 
epithelial ovarian cancer patients  5 
 
Variables 
N % 
Total 211 100 
Disease Stage    
I 52 24.6 
II 12 5.7 
III 133 63.0 
IV 14 6.6 
Tumor Grade    
1 34 16.1 
2 40 19.0 
3 137 64.9 
Histology (n=178)   
Clear Cell 16 7.6 
Endometrial 41 19.4 
Mucinous 18 8.5 
Müllerian 14 6.6 
Undifferentiated 36 17.1 
Other 1 0.5 
Sub-total (Non-serous) 126 59.7 
Serous 85 40.3 
Debulking Results    
Optimal  108 51.9 
Suboptimal 100 48.1 
Residual Tumor Size (cm)   
0 91 44.0 
> 0  116 56.0 
 N Median (range) 
Age (years)  208 58 (26 – 82) 
HIWI expression  211 0.06 (0 – 14.28) 
Let-7a expression 211 4.62 (0 – 655) 
 6 
 7 
 8 
 22 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
 10 
 11 
Table 2. Associations of HIWI expression and patient survival in epithelial ovarian 12 
cancer 13 
Relapse  Death Variable 
HR1 (95% CI2)  HR (95% CI) 
Univariate 
   
HIWI (Medium vs. Low or 
High) 
1.33 (0.863 – 2.05)  1.63 (1.06 – 2.52) 
Multivariate3   
 
HIWI (Medium vs. Low or 
High) 
1.38 (0.88 – 2.16)  1.89 (1.29 – 2.98) 
Age 1.02 (0.99 – 1.04)  1.01 (0.99 – 1.03) 
Disease stage 1.28 (0.88 – 1.87)  1.71 (1.08 – 2.71) 
Tumor grade 1.28 (0.89 – 1.84)  1.45 (0.97 – 2.17) 
Residual tumor size (>0 vs 0) 3.00 (1.62 – 5.57)  5.29 (2.50 – 11.20) 
Histological type (Serous vs 
non-serous) 
1.17 (0.75 – 1.82)  0.73 (0.46 – 1.13) 
Chemotherapy (yes vs no) 1.86 (0.55 – 6.24)  0.40 (0.17 – 0.95) 
   
 
1. HR: Hazards Ratio. 14 
2. CI: Confidence Interval. 15 
3. Adjusted for age at surgery, disease stage, tumor grade, residual tumor size, 16 
histological type and chemotherapy status. 17 
 18 
 19 
 23 
 1 
 2 
Table 3. Associations of HIWI expression with clinical and pathologic variables in 3 
epithelial ovarian cancer 4 
Variable N Low/ High HIWI 1 
n (%) 
Medium HIWI  
n (%) 
OR 2(95% CI3) p value 
Disease Stage    0.79 (0.42-1.48) 4 0.459 
1-2 64 42 (65.6) 22 (34.4) 
  
3-4 147 104 (70.8) 43 (29.2)   
Tumor Grade    1.32 (0.71-2.47) 0.382 
1-2 74 54 (73.0) 20 (27.0) 
  
3 137 92 (67.2) 45 (32.8) 
  
Residual Size (cm)    1.01 (0.56-1.83) 0.967 
0 91 63 (69.2) 28 (30.8) 
  
>0 116 80 (69.0) 36 (31.0) 
  
Histological Type    1.42 (0.79-2.56) 0.246 
Non-serous 126 91 (72.2) 35 (27.8) 
  
Serous 85 55 (64.7) 30 (35.3) 
  
Debulking Result    0.82 (0.45-1.47) 0.502 
Sub-optimal 100 67 (67.0) 33 (33.0) 
  
Optimal 108 77 (71.3) 31 (28.7) 
  
Chemotherapy Response    3.01 (1.50-6.04) 0.002 
Yes 128 98 (76.6) 30 (23.4) 
  
No 48 25 (52.1) 23 (47.9) 
  
1. HIWI expression: low, EI = 0 (undetectable); medium, 0 < EI <0.32; high, EI 5 
≥0.32. 6 
2. OR: odds ratio obtained from logistic regression analysis 7 
3. CI: confidential interval.  8 
4. In logistic regression analyses, the group of low or high HIWI expression was 9 
chosen as reference, and the second level of each variable as ‘event’.  10 
 11 
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 24 
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 9 
 10 
 11 
Table 4. Interaction of HIWI and let-7a expression in patient survival of epithelial 12 
ovarian cancer 13 
Relapse  Death Groups1 HIWI Let-7a  
Adj-HR 2 95% CI 3 Adj-HR 95% CI 
Group 1 Low/high Low  1.00  1.00  
Group 2 Low/high High  0.94 0.57 – 1.53 1.11 0.66 – 1.86 
Group 3 Medium Low  1.26 0.70 – 2.29 1.64 0.88 – 3.04 
Group 4 Medium High  1.45 0.74 -2.85 2.71 1.38 – 5.32 
1. Groups: group 1, low (EI = 0) or high (EI ≥0.32) HIWI and low (EI < 4.62) let-14 
7a; group 2, low or high HIWI and high let-7a (EI ≥ 4.62); group 3, medium (0 < 15 
EI <0.32) HIWI and low let-7a; and group 4, medium HIWI and high let-7a.   16 
2. Adj-HR: adjusted Hazard Ratio for patient age at surgery, disease stage, tumor 17 
grade, residual tumor size, histological type and chemotherapy status. 18 
3. CI: Confidence Interval. 19 
 20 
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Table 5. Stratification analyses for the associations of HIWI and let-7a expression 4 
with patient survival in epithelial ovarian cancer 5 
 6 
Death Stratified  
Variable 1 
Comparison Variable  
Adj-HR 2 95% CI 3 P value 
HIWI Let-7a     
Low/high High vs. low  1.19 0.71 – 2.01 0.511 
Medium High vs. low  1.61 0.75 – 3.43 0.218 
Let-7a HIWI     
Low Medium vs. low/high  1.63 0.86 – 3.08 0.137 
High Medium vs low/high  2.62 1.30 – 5.30 0.007 
1. HIWI: low (EI = 0, undetectable), medium (0 < EI <0.32), high (EI ≥0.32); 7 
let-7a: low (EI < 4.62), high (EI ≥ 4.62).   8 
2. Adj-HR: adjusted Hazard Ratio for patient age at surgery, disease stage, 9 
tumor grade, residual tumor size, histological type and chemotherapy status. 10 
3. CI: Confidence Interval. 11 
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Figure 1. Kaplan-Meier overall survival curves by levels of HIWI expression 
